Premium
Front Cover: A Series of 2‐((1‐Phenyl‐1H‐imidazol‐5‐yl)methyl)‐1H‐indoles as Indoleamine 2,3‐Dioxygenase 1 (IDO1) Inhibitors (ChemMedChem 14/2021)
Author(s) -
Zheng Yong,
Stafford Paul M.,
Stover Kurt R.,
Mohan Darapaneni Chandra,
Gupta Mayuri,
Keske Eric C.,
Schiavini Paolo,
Villar Laura,
Wu Fan,
Kreft Alexander,
Thomas Kiersten,
Raaphorst Elana,
Pasangulapati Jagadeesh P.,
Alla Siva R.,
Sharma Simmi,
Mittapalli Ramana R.,
Sagamanova Irina,
Johnson Shea L.,
Reed Mark A.,
Weaver Donald F.
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202100466
Subject(s) - indoleamine 2,3 dioxygenase , front cover , druggability , disease , brain disease , identification (biology) , neuroscience , chemistry , computational biology , cover (algebra) , medicine , psychology , biology , biochemistry , tryptophan , mechanical engineering , botany , amino acid , engineering , gene
The Front Cover illustrates the ‘molecule to mind’ structural hierarchy of pathology and symptoms arising from Alzheimer's disease. Although Alzheimer's presents as a disorder of thought, memory, and cognition, it is a disease that we seek to treat not at the cellular level, but at the molecular level. Given that the brain is the most complex structure in the universe, and that Alzheimer's is the most complex disease of brain, the search for new treatments must address all possible avenues. The brain's immune system is an important emerging druggable target; we describe our identification of indoleamine 2,3‐dixoygenase inhibitors as putative disease modifying therapies for Alzheimer's. More information can be found in the Communication by Donald F. Weaver et al.